Cargando…
SGLT2-inhibitors and euglycemic diabetic ketoacidosis in COVID-19 pandemic era: a case report
Autores principales: | Secinaro, Enzo, Ciavarella, Simone, Rizzo, Giulia, Porreca, Ettore, Vitacolonna, Ester |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9206855/ https://www.ncbi.nlm.nih.gov/pubmed/35718795 http://dx.doi.org/10.1007/s00592-022-01909-9 |
Ejemplares similares
-
Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors
por: Chow, Erica, et al.
Publicado: (2023) -
Euglycemic Diabetic Ketoacidosis With SGLT-2 Inhibitor
por: Manas, F N U, et al.
Publicado: (2021) -
Euglycemic Diabetic Ketoacidosis after Discontinuing SGLT2 Inhibitor
por: Alhemeiri, Mohamed, et al.
Publicado: (2022) -
A Case of SGLT2 Inhibitor-Induced Euglycemic Diabetic Ketoacidosis
por: Rao, Shiavax J, et al.
Publicado: (2022) -
THU387 Euglycemic Diabetic Ketoacidosis And SGLT-2 Inhibitor Use
por: Abrahimi, Nora, et al.
Publicado: (2023)